These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 29120234)

  • 21. Metabolic and analytic considerations in the design of immunoassays.
    Weinryb I; Shroff JR; Olson DR
    Drug Metab Rev; 1979; 10(2):271-83. PubMed ID: 233213
    [No Abstract]   [Full Text] [Related]  

  • 22. Matrix effect in ligand-binding assay: the importance of evaluating emerging technologies.
    Crisino RM; Luo L; Geist B; Zoghbi J; Spriggs F
    Bioanalysis; 2014 Apr; 6(8):1033-6. PubMed ID: 24830885
    [No Abstract]   [Full Text] [Related]  

  • 23. Understanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical Relevance.
    Song S; Yang L; Trepicchio WL; Wyant T
    J Immunol Res; 2016; 2016():3072586. PubMed ID: 27340678
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity testing strategy and bioanalytical assays for antibody-drug conjugates.
    Hoofring SA; Lopez R; Hock MB; Kaliyaperumal A; Patel SK; Swanson SJ; Chirmule N; Starcevic M
    Bioanalysis; 2013 May; 5(9):1041-55. PubMed ID: 23641695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How the bioanalytical scientist plays a key role in interdisciplinary project teams in the development of biotherapeutics - a reflection of the European Bioanalysis Forum.
    Dudal S; Staack RF; Stoellner D; Fjording MS; Vieser E; Pascual MH; Brudny-Kloeppel M; Golob M
    Bioanalysis; 2014 May; 6(10):1339-48. PubMed ID: 24958118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrating internal and external bioanalytical support to deliver a diversified pharmaceutical portfolio.
    Summerfield SG; Evans C; Spooner N; Dunn JA; Szapacs ME; Yang E
    Bioanalysis; 2014 May; 6(10):1311-9. PubMed ID: 24958115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current challenges in assessing immunogenicity.
    Shankar G
    Bioanalysis; 2019 Sep; 11(17):1543-1546. PubMed ID: 31617390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transfer from research/academia to clinical/regulated.
    Chowdhury F; Williams A
    Bioanalysis; 2016 Oct; 8(20):2169-76. PubMed ID: 27628669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Key elements of bioanalytical method validation for macromolecules.
    Kelley M; DeSilva B
    AAPS J; 2007 May; 9(2):E156-63. PubMed ID: 17614356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New bioanalytical technologies and concepts: worth the fuss?
    Smith DA
    Bioanalysis; 2013 Aug; 5(16):1969-73. PubMed ID: 23937131
    [No Abstract]   [Full Text] [Related]  

  • 31. A seat at the table: the benefits of integrating bioanalytical sciences into development project teams.
    Aubry AF
    Bioanalysis; 2014 May; 6(10):1291-3. PubMed ID: 24958113
    [No Abstract]   [Full Text] [Related]  

  • 32. Imaging of latent fingerprints through the detection of drugs and metabolites.
    Hazarika P; Jickells SM; Wolff K; Russell DA
    Angew Chem Int Ed Engl; 2008; 47(52):10167-70. PubMed ID: 19039814
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical immunogenicity of the d-amino acid peptide therapeutic etelcalcetide: Method development challenges and anti-drug antibody clinical impact assessments.
    Kroenke MA; Weeraratne DK; Deng H; Sloey B; Subramanian R; Wu B; Serenko M; Hock MB
    J Immunol Methods; 2017 Jun; 445():37-44. PubMed ID: 28274835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper.
    Gorovits B; Alley SC; Bilic S; Booth B; Kaur S; Oldfield P; Purushothama S; Rao C; Shord S; Siguenza P
    Bioanalysis; 2013 May; 5(9):997-1006. PubMed ID: 23641692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bioanalysis of biotherapeutics at a crossroad.
    Ezan E
    Bioanalysis; 2011 Mar; 3(5):469-71. PubMed ID: 21388257
    [No Abstract]   [Full Text] [Related]  

  • 36. Drug metabolites and immunoassays.
    Gault MH
    Clin Chem; 1994 Oct; 40(10):1863-4. PubMed ID: 7923762
    [No Abstract]   [Full Text] [Related]  

  • 37. International harmonization of bioanalytical guidance.
    Bansal SK; Arnold M; Garofolo F
    Bioanalysis; 2010 Apr; 2(4):685-7. PubMed ID: 21083262
    [No Abstract]   [Full Text] [Related]  

  • 38. [Development of the methods for measuring drugs and their metabolites].
    Ann Biol Clin (Paris); 1985; 43(4):543-57. PubMed ID: 4091315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bioanalytical outsourcing strategy at Janssen Research and Development.
    Verhaeghe T
    Bioanalysis; 2014 May; 6(10):1321-7. PubMed ID: 24958116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biomarkers, PK and immunogenicity: are we ready for integration?
    Stevenson LF
    Bioanalysis; 2016 Nov; 8(22):2287-2289. PubMed ID: 27737564
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.